These results indicate that either the use of mAb possessing strong ADCC/CDC activity or the complete inhibition of podoplanin–CLEC-2 binding by the combined administration of anti-PLAG3 and anti-PLAG4 mAbs may be required for inducing complete tumor remission. Here, PDPN is linked to neoplasm.